Adjuvant therapy for resectable rectal adenocarcinoma

✍ Scribed by Kenneth S. Hu; Louis B. Harrison

• Publisher: John Wiley and Sons
• Year: 2000
• Tongue: English
• Weight: 125 KB
• Volume: 19
• Category: Article
• ISSN: 8756-0437
• DOI: 10.1002/ssu.4

✦ Synopsis

Abstract

The mainstay of treatment for rectal cancer over the past 100 years has been surgical resection. However, for the majority of rectal cancers treated conventionally by resection alone, locoregional recurrence is the major mode of failure. Over the past several decades, significant progress has been made in developing effective adjuvant regimens. In the United States, postoperative chemoradiation is standard treatment for T3 or node‐positive patients. However, preoperative radiation with or without chemotherapy decreases local recurrence, increases sphincter preservation, and may improve survival. The purpose of this article is to review the role of adjuvant therapy in resectable rectal cancers and to update the status of ongoing randomized trials. Semin. Surg. Oncol. 19:336–349, 2000. © 2000 Wiley‐Liss, Inc.